Cargando…
Prostaglandin terminal synthases as novel therapeutic targets
Non-steroidal anti-inflammatory drugs (NSAIDs) exert their anti-inflammatory and anti-tumor effects by reducing prostaglandin (PG) production via the inhibition of cyclooxygenase (COX). However, the gastrointestinal, renal and cardiovascular side effects associated with the pharmacological inhibitio...
Autor principal: | HARA, Shuntaro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Japan Academy
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5743848/ https://www.ncbi.nlm.nih.gov/pubmed/29129850 http://dx.doi.org/10.2183/pjab.93.044 |
Ejemplares similares
-
Therapeutic Potential of Hematopoietic Prostaglandin D(2) Synthase in Allergic Inflammation
por: Rittchen, Sonja, et al.
Publicado: (2019) -
Microsomal prostaglandin E synthase-1: the inducible synthase for prostaglandin E(2)
por: Sampey, Annaleise V, et al.
Publicado: (2005) -
Genetic-deletion of Cyclooxygenase-2 Downstream Prostacyclin Synthase Suppresses Inflammatory Reactions but Facilitates Carcinogenesis, unlike Deletion of Microsomal Prostaglandin E Synthase-1
por: Sasaki, Yuka, et al.
Publicado: (2015) -
Prostaglandin and prostaglandin receptors: present and future promising therapeutic targets for pulmonary arterial hypertension
por: Zeng, Cheng, et al.
Publicado: (2023) -
Microsomal prostaglandin E synthase-1 in both cancer cells and hosts contributes to tumour growth, invasion and metastasis
por: Kamei, Daisuke, et al.
Publicado: (2009)